Duloxetine Delayed-Release Capsules
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
37 recalls, newest first
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Subpotent Drug
Failed Impurities/Degradation Specifications: Out-of-specification results obtained for related impurities and slightly lower than the established level of the Hydrocortisone Assay obtained during stability testing.
CGMP Deviations: sterile water not used for production
CGMP Deviations: sterile water not used for production
Presence of Foreign Tablets: Potential presence of Fludrocortisone Acetate Tablet USP 0.1 mg within the Methotrexate 2.5 mg 100-count Bottle.
Cross contamination with other products
Cross contamination with other products
CGMP Deviations and Presence of Particulate Matter: Glass
Product Mix Up. A bottle of Phenazopyridine HCl tablets USP 100 mg contained Phenobarbital tablets 16.2 mg.
Failed Impurities/Degradation Specifications
Failed Impurities/Degradation Specifications
Labeling: Wrong Barcode
Labeling: Label mix-up - ephedrine syringes mislabeled as phenylephrine.
Failed Tablet/Capsule Specifications: There is a potential for the imprint, M 122, to be missing on some tablets.
Presence of Foreign Substance; Broken metal piece found embedded in tablet.
cGMP Deviations
Failed dissolution specifications: out-of-specification bempedoic acid dissolution at the 0-month timepoint.
Failed Dissolution Specifications
CGMP Deviations
Failed Stability Specifications
Failed Stability Specifications
Subpotent Drug: Out of specification for assay
Chemical Contamination; presence of benzene.
CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.